Details of the Drug Combinations

General Information of This Drug (ID: DMA12HL)

Drug Name
Azelnidipine   DMA12HL
Synonyms
Azelnidipine; Azelnidipine [INN]; Calblock; RS-9054; 123524-52-7; 3,5-PYRIDINEDICARBOXYLIC ACID, 2-AMINO-1,4-DIHYDRO-6-METHYL-4-(3-NITROPHENYL)-, 3-[1-(DIPHENYLMETHYL)-3-AZETIDINYL] 5-(1-METHYLETHYL) ESTER; 3-(1-Benzhydrylazetidin-3-yl) 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; C33H34N4O6; CS 905; CS-905; DSSTox_CID_120; DSSTox_GSID_20120; DSSTox_RID_75382; MFCD00865803; NCGC00167436-01; NCGC00167436-02
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1]
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

21 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Artemisinin + Azelnidipine DCQA4PK Artemisinin DD2 (Cell Line: DD2) [2]
Azelnidipine + Lumefantrine DC0J6MV Lumefantrine DD2 (Cell Line: DD2) [2]
Azelnidipine + Lumefantrine DC9ZVCH Lumefantrine Hepatoblastoma (Cell Line: HB3) [2]
Azelnidipine + Diltiazem DCK1H8Z Diltiazem DD2 (Cell Line: DD2) [2]
Azelnidipine + Diltiazem DC2YD1Y Diltiazem Hepatoblastoma (Cell Line: HB3) [2]
Azelnidipine + Idarubicin DCS5OLC Idarubicin Glioblastoma? (Cell Line: T98G) [2]
Azelnidipine + Methylene blue DC3QYM7 Methylene blue DD2 (Cell Line: DD2) [2]
Azelnidipine + Methylene blue DCV10FT Methylene blue Hepatoblastoma (Cell Line: HB3) [2]
Azelnidipine + Artemisinin DCJ1ESB Artemisinin DD2 (Cell Line: DD2) [2]
Azelnidipine + Artemisinin DC4QGJH Artemisinin Hepatoblastoma (Cell Line: HB3) [2]
Azelnidipine + Chloroquine DCYHMQH Chloroquine DD2 (Cell Line: DD2) [2]
Azelnidipine + Piperaquine DCT27DK Piperaquine Hepatoblastoma (Cell Line: HB3) [2]
Azelnidipine + Mefloquine DC31ZOK Mefloquine DD2 (Cell Line: DD2) [2]
Azelnidipine + Mefloquine DCHM2TI Mefloquine Hepatoblastoma (Cell Line: HB3) [2]
Diltiazem + Azelnidipine DCLE5H4 Diltiazem DD2 (Cell Line: DD2) [2]
Lumefantrine + Azelnidipine DCARNW7 Lumefantrine DD2 (Cell Line: DD2) [2]
Lumefantrine + Azelnidipine DCA0BA3 Lumefantrine Hepatoblastoma (Cell Line: HB3) [2]
Mefloquine + Azelnidipine DCKQBHT Mefloquine DD2 (Cell Line: DD2) [2]
Mefloquine + Azelnidipine DCZV3W0 Mefloquine Hepatoblastoma (Cell Line: HB3) [2]
NITD609 + Azelnidipine DCLP92R NITD609 DD2 (Cell Line: DD2) [2]
NITD609 + Azelnidipine DC5D37D NITD609 Hepatoblastoma (Cell Line: HB3) [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 21 DrugCom(s)
1 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Azelnidipine + Perindopril DC9NWQQ Perindopril Cerebral Small Vessel Diseases [4]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4 ClinicalTrials.gov (NCT01819441) Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients